Nitto Group Report 2017

23/44

22Nitto Group Report 2017Creating micropores on the skin to apply a transdermal patchXTRATA® Perme-Roll AIR™ is applied to the area within the dotted line.Expanding Contract Manufacturing of OligonucleotidesNitto PassPort® SystemAgreement with Bristol-Myers Squibb to Develop Therapies for NASH and CirrhosisXTRATA® Perme-Roll AIR™Transdermal drug delivery patchesThe Nitto Group boasts the leading share of the market for contract manufacturing of oligonucleotide medicines, which are expected to be effective for cancer and other difcult-to-cure diseases.In October 2016, Nitto acquired the assets of Irvine Pharmaceutical Services and Avrio Biopharmaceuticals of the U.S. via Nitto Denko Avecia Inc. to establish Nitto Avecia Pharma Services Inc. This acquisition allows the Nitto Group to broaden its pharmaceutical analytical capabilities and provide aseptic ll & nish services.We will remain committed to providing services that help to accelerate the development of oligonucleotide medicines in its bid to deliver new drugs into the hands of patients as soon as possible.The Nitto PassPort® System is a novel drug delivery system that combines technology for painless and safe creation of micropores on the skin surface with advanced drug patch technology. Capable of efciently delivering substances that cannot be absorbed into the skin as they are, such as polymer bio-pharmaceuticals, which include peptides, oligonucleotides, and proteins, and hydrophilic drugs, this innovative transdermal drug delivery platform allows patients to receive drugs that are currently available only via injection or infusion, and is able to control the duration and quantity of the delivered drugs by optimizing the number and size of micopores, as well as the formulation.At present, Nitto is working on this platform with multiple pharmaceutical manufacturers to accelerate its commercialization.Nitto has been working to develop brosis therapy through the use of small interfering RNA (siRNA) since 2008. One of Nitto’s leading investigational products thus developed has been granted fast track designation by the U.S. Food and Drug Administration for indications of liver brosis and cirrhosis secondary to advanced non-alcoholic steatohepatitis (NASH) and to the hepatitis C virus (HCV).In November 2016, Nitto and Bristol-Myers Squibb (BMS) of the U.S. entered into an agreement granting BMS exclusive worldwide rights for the development, manufacture, and commercialization of Nitto’s leading investigational product for NASH and liver cirrhosis. The agreement is expected to accelerate development of this investigational product, thereby delivering the therapy to patients as early as possible.A thinner model of the XTRATA® Perme-Roll™ transparent lm roll has made its debut. Only one-fourth the thickness of the previous model, XTRATA® Perme-Roll AIR™ covers injured skin surfaces to make the wound dressings impermeable to bacteria and liquids. Stretching easily to gently t the contours of the body, it feels as if nothing is on the skin at all. The unique STRATAGEL® soft gel adhesive ts so perfectly to the skin surface that wound dressings can be gently removed with minimum damage to the stratum cornea.Transdermal drug delivery patches are medicated adhesive patches placed on the skin to deliver drugs. Unlike internal medicine, they neither irritate the digestive tract nor the liver, and do not cause pain like injections using needles. They also help to alleviate adverse drug reactions due to rapid drug absorption by controlling dosages.Nitto’s technologies have produced medicated adhesive patches for local anesthesia and a broad range of indications, including ischemic heart disease, asthma, and hypertension, thereby helping patients to ease their concerns and burdens.FineFineFinePolymer designCooperativeR&DPenetrationenhancerProtectionof horny layerDrugstabilityReleasecontrolImprovementof drugabsorptionMinimizedskinirritationSelection oftarget drugsProposals for the Future!Proposals for the Future!Applicator deviceAssembled poratorTransdermal patch